A Novel Amphibian Antimicrobial Peptide, Phylloseptin-PV1, Exhibits Effective Anti-staphylococcal Activity Without Inducing Either Hepatic or Renal Toxicity in Mice
Yue Liu,Daning Shi,Jin Wang,Xiaoling Chen,Mei Zhou,Xinping Xi,Jianming Cheng,Chengbang Ma,Tianbao Chen,Chris Shaw,Lei Wang
DOI: https://doi.org/10.3389/fmicb.2020.565158
IF: 5.2
2020-10-26
Frontiers in Microbiology
Abstract:In order to part address the problem of drug-resistant pathogens, antimicrobial peptides (AMPs) have been proposed as alternatives to traditional antibiotics. Herein, a novel phylloseptin peptide, named phylloseptin-PV1 (PPV1), is described from the defensive skin secretion of the Neotropical white-lined leaf frog, <i>Phyllomedusa vaillantii</i>. The peptide was synthesized by solid phase peptide synthesis (SPPS) and purified by RP-HPLC, prior to assessment of its biological activities. PPV1 not only demonstrated potent antimicrobial activity against planktonic ESKAPE microorganisms and the yeast, <i>Candida albicans</i>, but also inhibited and eradicated <i>Staphylococcus aureus</i> and MRSA biofilms. The antimicrobial mechanism was shown to include permeabilization of target cell membranes. The <i>in vivo</i> antimicrobial activity of the peptide was then evaluated using mice. PPV1 also exhibited antiproliferative activity against the cancer cell lines, H157, MCF-7, and U251MG, but had a lower potency against the normal cell line, HMEC-1. Although, the peptide possessed a moderate hemolytic action on mammalian red blood cells <i>in vitro</i>, it did not induce significant hepatic or renal toxicity in injected infected mice. These studies have thus found PPV1 to be a potent phylloseptin group AMP, which can effectively inhibit staphylococci, both <i>in vitro</i> and <i>in vivo</i>, without eliciting toxicity. These data thus provide support for further evaluation of PPV1 as a novel antimicrobial agent with therapeutic potential.
microbiology